The present invention relates to a sustained-release microsphere containing a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof and a sustained-release formulation. More specifically, the present invention relates to a sustained-release formulation comprising a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof, wherein the formulation includes a sustained-release microsphere containing the GLP-1 receptor agonist or the pharmaceutically acceptable salt thereof, one type of low-viscosity PLGA with an intrinsic viscosity of 0.14 to 0.24 dL/g, and two or more types of high-viscosity PLGA with an intrinsic viscosity of 0.32 to 0.60 dL/g and is free of problems associated with initial burst release and delayed release, thus enabling prolonged drug release and excellent bioavailability.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; allergy medications; biological preparations for medical or veterinary purposes for the treatment of central precocious puberty, endometriosis, uterine fibroids, prostate cancer and breast cancer; drugs for medical purposes for the treatment of central precocious puberty, endometriosis, uterine fibroids, prostate cancer and breast cancer; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treatment of respiratory organs
The present invention relates to natriuretic peptide analogues with enhanced stability and a pharmaceutical composition comprising same. Exhibiting a prolonged in vivo half-life, high bioavailability, and a high bone growth rate as well as being relatively short sequence length, a C-type natriuretic peptide analogue according to an embodiment of the present invention has advantages of being easy to synthesize and reducing production costs, and thus is expected to be effectively used in compositions for promoting growth and in the prevention or treatment of bone-related diseases.
The sustained release formulation with an increased initial release amount according to the present invention exhibits a rapid release effect within 24 hours after administration and can exhibit a continuous sustained release effect thereafter, thereby achieving long-term drug efficacy persistence and an initial rapid release purpose at the same time. Found to have excellent bioavailability and be safe in the human body, the sustained-release formulation comprising microspheres containing leuprorelin according to the present invention thus can be effectively and safely used for the treatment of various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine myoma, prostate cancer, pulmonary pre-menopausal cancer, and central precocious puberty.
The present invention relates to a novel antibody and a use thereof, and more specifically, to: an antibody-drug conjugate or a bispecific antibody comprising the antibody produced by substituting an existing antibody sequence or an antigen-binding fragment thereof, wherein the antibody does not have any glycation-related substances generated in a production process; a pharmaceutical composition comprising the antibody-drug conjugate or bispecific antibody for preventing or treating cancer; a nucleic acid encoding the antibody or an antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; and a method for preparing an antibody or an antigen-binding fragment thereof.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
7.
SUSTAINED RELEASE FORMULATION COMPOSITION COMPRISING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to sustained-release microspheres which include semaglutide or a pharmaceutically acceptable salt thereof, and a sustained-release formulation composition including the same, which enable long-term sustained release of a drug without an initial burst, and have no release delay (lag phase) while having excellent bioavailability.
The present invention relates to a sustained-release microsphere containing a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof and a sustained-release formulation. More specifically, the present invention relates to a sustained release formulation comprising a GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof, wherein the formulation includes sustained release microsphere containing the GLP-1 receptor agonist or a pharmaceutically acceptable salt thereof, one type of low-viscosity PLGA with an intrinsic viscosity of 0.14 to 0.24 dL/g, and two or more types of high-viscosity PLGA with an intrinsic viscosity of 0.32 to 0.60 dL/g and is free of problems associated with initial burst release and delayed release, thus enabling prolonged drug release and excellent bioavailability.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
9.
Antibody binding specifically to MUC1 and use thereof
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C12N 15/62 - DNA sequences coding for fusion proteins
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present invention relates to a novel antibody and a use thereof, and more specifically, to: an antibody-drug conjugate or a bispecific antibody comprising the antibody or an antigen-binding fragment thereof, wherein the antibody does not have any glycation-related substances generated in a production process by substituting an existing antibody sequence; a pharmaceutical composition containing the antibody-drug conjugate or bispecific antibody for preventing or treating cancer; a nucleic acid encoding the antibody or antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; and a method for preparing an antibody or an antigen-binding fragment thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present invention relates to a novel antibody and a use thereof, and more specifically, to: an antibody-drug conjugate or a bispecific antibody comprising the antibody or an antigen-binding fragment thereof, wherein the antibody does not have any glycation-related substances generated in a production process by substituting an existing antibody sequence; a pharmaceutical composition containing the antibody-drug conjugate or bispecific antibody for preventing or treating cancer; a nucleic acid encoding the antibody or antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; and a method for preparing an antibody or an antigen-binding fragment thereof.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C12N 15/62 - DNA sequences coding for fusion proteins
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
13.
SUSTAINED RELEASE FORMULATION COMPOSITION COMPRISING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to sustained-release microspheres which include semaglutide or a pharmaceutically acceptable salt thereof, and a sustained-release formulation composition including the same, which enable long-term sustained release of a drug without an initial burst, and have no release delay (lag phase) while having excellent bioavailability.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
14.
SUSTAINED RELEASE FORMULATION COMPOSITION COMPRISING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention relates to sustained-release microspheres containing semaglutide or a pharmaceutically acceptable salt thereof and a sustained-release formulation composition comprising same, which enable long-term sustained release of the drug without an initial burst, have no lag phase and have excellent bioavailability.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
15.
Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof
A GLP-1 receptor agonist has effects of reducing serious side effects due to long-term use of levodopa when administered in combination with levodopa, and also effects of alleviating or improving abnormal involuntary movements (AIMs) caused by levodopa. A method for prevention or treatment of levodopa-induced dyskinesia according to an embodiment of the present disclosure includes administering a glucagon-like peptide-1 (GLP-1) receptor agonist to a patient.
The USA, as represented by the Secretary, Department of Health and Human Services (USA)
Peptron, Inc. (USA)
Inventor
Kim, Dong Seok
Kim, Hee Kyung
Greig, Nigel H.
Abstract
The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the conjugate. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate in which the antibody or the antigen-binding fragment thereof is conjugated with a drug can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C12N 15/62 - DNA sequences coding for fusion proteins
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present invention relates to a pharmaceutical composition for treatment or prevention of levodopa-induced dyskinesia. When administered in combination with levodopa, the GLP-1 receptor agonist or a controlled release formulation thereof according to the present invention exhibits the effects of decreasing serious side effects caused by long-term administration of levodopa and reducing levodopa-induced, non-spontaneous dyskinesia.
The present invention relates to a pharmaceutical composition for treatment or prevention of levodopa-induced dyskinesia. When administered in combination with levodopa, the GLP-1 receptor agonist or a controlled release formulation thereof according to the present invention exhibits the effects of decreasing serious side effects caused by long-term administration of levodopa and reducing levodopa-induced, non-spontaneous dyskinesia.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
20.
Antibody binding specifically to MUC1 and use thereof
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C12N 15/62 - DNA sequences coding for fusion proteins
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUCl-related disease, for example, cancer.
The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) and a use thereof and, more particularly, to an anti-MUC1 antibody or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for prevention or treatment of cancer, comprising the same conjugate or bispecific antibody, and a nucleic acid encoding the same antibody or an antigen-binding fragment thereof, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, an antibody binding specifically to MUC1 or an antigen-binding fragment thereof shows outstanding affinity and binding force to MUC1 and an antibody-drug conjugate in which the antibody or an antigen-binding fragment thereof is conjugated with a drug can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMEN (USA)
PEPTRON, INC. (Republic of Korea)
Inventor
Kim, Dong Seok
Kim, Hee Kyung
Greig, Nigel H.
Abstract
The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
24.
METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)
Inventor
Kim, Dong, Seok
Kim, Hee, Kyung
Greig, Nigel, H.
Abstract
The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
25.
MULTIFUNCTIONAL SKIN-PERMEATING PEPTIDE HAVING WHITENING, SKIN ELASTICITY, WRINKLE IMPROVEMENT, AND WOUND HEALING ACTIVITIES
The present invention relates to a multifunctional peptide and use of same, the multifunctional peptide having whitening, elasticity, and wrinkle improvement effects based on a skin-permeating function, and more specifically, to a method for utilizing, as a raw ingredient in functional cosmetics and medicine, a multifunctional peptide having the effects of skin permeation, melanin production inhibition, collagen production promotion, and keratinous stem cell proliferation promotion. The multifunctional skin-permeating peptide, according to the present invention, has the characteristic of easily permeating skin and is exceptionally effective in inhibiting melanin synthesis and promoting collagen synthesis and keratinous stem cell proliferation, thus rendering the peptide useful, even independently, as cosmetics or medicine for whitening skin, improving skin elasticity, improving wrinkles, or healing wounds.
The present invention relates to a multifunctional peptide and use of same, the multifunctional peptide having whitening, elasticity, and wrinkle improvement effects based on a skin-permeating function, and more specifically, to a method for utilizing, as a raw ingredient in functional cosmetics and medicine, a multifunctional peptide having the effects of skin permeation, melanin production inhibition, collagen production promotion, and keratinous stem cell proliferation promotion. The multifunctional skin-permeating peptide, according to the present invention, has the characteristic of easily permeating skin and is exceptionally effective in inhibiting melanin synthesis and promoting collagen synthesis and keratinous stem cell proliferation, thus rendering the peptide useful, even independently, as cosmetics or medicine for whitening skin, improving skin elasticity, improving wrinkles, or healing wounds.
An ultrasonic atomizer for maintaining a constant temperature of an ultrasonic vibration generating unit by decreasing a temperature at the periphery of the ultrasonic vibration generating unit even under an environment in which the ultrasonic vibration generating unit is exposed to a high temperature is provided. The ultrasonic atomizer includes: an ultrasonic vibration generating unit which generates ultrasonic waves and atomizes a spray material; a nozzle unit; a housing; and a heat exchange unit which surrounds the ultrasonic vibration generating unit, includes a separation wall which divides the heat exchange unit into heat exchange chambers, and cools heat generated from the ultrasonic vibration generating unit, in which the heat exchange chambers include: a heating chamber; and a cooling chamber which surrounds the heating chamber, and includes a cooling space by being isolated with the heat exchange unit abutting the heating chamber between the cooling chamber and the heating chamber.
B05B 15/00 - Details of spraying plant or spraying apparatus not otherwise provided forAccessories
B05B 17/06 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods using ultrasonic vibrations
F28F 13/10 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by affecting the pattern of flow of the heat-exchange media by imparting a pulsating motion to the flow, e.g. by sonic vibration
F28D 1/06 - Heat-exchange apparatus having stationary conduit assemblies for one heat-exchange medium only, the media being in contact with different sides of the conduit wall, in which the other heat-exchange medium is a large body of fluid, e.g. domestic or motor car radiators with the heat-exchange conduits forming part of, or being attached to, the tank containing the body of fluid
F28D 7/10 - Heat-exchange apparatus having stationary tubular conduit assemblies for both heat-exchange media, the media being in contact with different sides of a conduit wall the conduits being arranged one within the other, e.g. concentrically
An ultrasonic atomizer for maintaining a constant temperature of an ultrasonic vibration generating unit by decreasing a temperature at the periphery of the ultrasonic vibration generating unit even under an environment in which the ultrasonic vibration generating unit is exposed to a high temperature is provided. The ultrasonic atomizer includes: an ultrasonic vibration generating unit which generates ultrasonic waves and atomizes a spray material; a nozzle unit; a heat exchange unit which cools heat generated from the ultrasonic vibration generating unit; and a housing which has heat exchange chambers, where the heat exchange chambers include: a vortex chamber which is positioned in the housing at the periphery of the ultrasonic vibration generating unit and guides a vortex flow; and a thermal insulation chamber which surrounds the vortex chamber and has a separation wall which abuts the vortex chamber, and includes an internal thermal insulation space.
B05B 17/06 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods using ultrasonic vibrations
F28F 13/10 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by affecting the pattern of flow of the heat-exchange media by imparting a pulsating motion to the flow, e.g. by sonic vibration
Provided is an ultrasonic atomizer capable of maintaining a set temperature of an ultrasonic vibration generation unit even in an environment in which same is exposed to high temperatures by cooling the temperature in the periphery thereof. The ultrasonic atomizer comprises: an ultrasonic vibration generation unit for generating ultrasonic waves and atomizing spray material; a nozzle unit comprising a spray fluid passageway through which the spray material moves along the central shaft penetrating the center of the ultrasonic vibration generation unit, and a nozzle tip for receiving the spray material from one end of the spray fluid passageway and spraying the spray material through the other end of the spray fluid passageway; a housing surrounding the ultrasonic vibration generation unit and having a plurality of heat-exchange chambers therein; and a heat-exchange unit, surrounding the ultrasonic vibration generation unit and comprising a barrier for separating the plurality of heat-exchange chambers, for cooling the heat generated by the ultrasonic vibration generation unit, and wherein the plurality of heat-exchange chambers comprise: a heating chamber, located in the periphery of the ultrasonic vibration generation unit in the interior of the housing, comprising a heating space; and a cooling chamber surrounding the heating chamber and distanced therefrom with the heat-exchange unit, which is in contact with the heating chamber, therebetween, and comprising a cooling space.
B05B 17/06 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods using ultrasonic vibrations
Provided is an ultrasonic atomizer capable of maintaining a set temperature of an ultrasonic vibration generation unit even in an environment in which same is exposed to high temperatures by cooling the temperature in the periphery thereof. The ultrasonic atomizer comprises: an ultrasonic vibration generation unit for generating ultrasonic waves and atomizing spray material; a nozzle unit comprising a spray fluid passageway through which the spray material moves along the central axis penetrating the center of the ultrasonic vibration generation unit, and a nozzle tip for receiving the spray material from one end of the spray fluid passageway and spraying the spray material through the other end of the spray fluid passageway; a heat-exchange unit, surrounding the ultrasonic vibration generation unit, for cooling the heat generated from the ultrasonic vibration generation unit; and a housing surrounding the ultrasonic vibration generation unit and the heat-exchange unit and having a plurality of heat-exchange chambers in the interior thereof, wherein the plurality of heat-exchange chambers comprise: a vortex chamber, located in the periphery of the ultrasonic vibration generation unit in the interior of the housing, for guiding the flow of a vortex flow; and an insulation chamber surrounding the vortex chamber, having a barrier in contact therewith, and comprising an inner insulating space.
B05B 17/06 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods using ultrasonic vibrations
